Psoriasis Clinical Trials in Houston

Showing 41-60 of 101 trials

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

NCT04655313

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:

PsoriasisPlaque Psoriasis

Arcutis Biotherapeutics, Inc.20 participantsStarted Nov 2020

Mountain Brook, Alabama, United States • Scottsdale, Arizona, United States • Fountain Valley, California, United States +14 more locations

COMPLETEDPHASE3< 1 mile

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662

The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.

Chronic Plaque Psoriasis

Biogen400 participantsStarted Dec 2002

Irvine, California, United States • San Francisco, California, United States • Santa Monica, California, United States +43 more locations

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Safety and Tolerability of Repeat Courses of IM Alefacept

Psoriasis Trials in Other Cities

Vascular Inflammation in Psoriasis - Apremilast

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

CP-690-550 Ointment For Chronic Plaque Psoriasis

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

A Study of Mirikizumab in Participants With Plaque Psoriasis

Other Conditions in Houston